At 8.1% CAGR, Europe Organ Preservation Solution Market is Projected to be worth US$ 1,59,990.22 thousand by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe organ preservation solution market was valued at US$ 86,522.54 thousand in 2023 and is expected to reach US$ 1,59,990.22 thousand by 2031, registering a CAGR of 8.1% from 2023 to 2031. Strategic initiatives by market players and rising need for organ transplantation are among the critical factors attributed to drive the Europe organ preservation solution market growth.

Various market players focus on product launches or strategic collaborations to develop advanced products that help ease the treatment of chronic disorders. There have been various recent developments, such as product launches, mergers, and acquisitions in recent years.

• In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart System for using it with organs procured from donors after circulatory death. The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donors-after-circulatory-death (DCD) hearts.
• In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system-BAROguard. The BAROguard system combines Paragonix's advanced hypothermic preservation technology with automated continuous and active airway pressure control. This control ensures the maintenance of optimal temperature range and a clinically recommended inflation pressure range for donor's lungs throughout their transfer from donors to recipients. This novel combination of advanced technologies further reinforces the company's ongoing commitment to improving and redefining the standard of care within the field of transplant medicine.
• In April 2024, the Mayo Clinic and the Terasaki Institute for Biomedical Innovation collaborated to improve organ transplant outcomes. Mayo Clinic biomedical researchers and Terasaki Institute scientists plan to collaborate on two main study areas: real-time monitoring of donated organ health from procurement to transplant surgery and the development of predictive technologies to identify transplant recipients with a higher risk of rejection. This will involve creating prognostic signatures and assays for antibody-mediated rejection of organ transplants. The initial projects are expected to be completed within 24-30 months.

Thus, a surge in product approvals, launches, and strategic collaborations is likely to create considerable growth opportunities for the organ preservation solution market in the future. 

On the contrary, the expensive organ transplant surgeries hamper the growth of Europe organ preservation solution market.

Based on product, the Europe organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held 35.9% market share in 2023, amassing US$ 31,027.72 thousand. It is projected to garner US$ 57,499.73 thousand by 2031 to register 8.1% CAGR during 2023-2031.

In terms of application, the Europe organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held 45.9% share of Europe organ preservation solution market in 2023, amassing US$ 39,738.22 thousand. It is anticipated to garner US$ 74,624.09 thousand by 2031 to expand at 8.3% CAGR during 2023-2031.

By type, the Europe organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held 59.6% share of Europe organ preservation solution market in 2023, amassing US$ 51,541.18 thousand. It is projected to garner US$ 96,902.84 thousand by 2031 to expand at 8.3% CAGR from 2023 to 2031.

Based on end user, the Europe organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held 54.2% share of Europe organ preservation solution market in 2023, amassing US$ 46,878.17 thousand. It is predicted to garner US$ 88,193.58 thousand by 2031 to expand at 8.3% CAGR between 2023 and 2031.

Based on country, the Europe organ preservation solution market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.4% share of Europe organ preservation solution market in 2023. It was assessed at US$ 25,472.24 thousand in 2023 and is likely to hit US$ 45,181.24 thousand by 2031, registering a CAGR of 7.5% during 2023-2031.

Key players operating in the Europe organ preservation solution market are XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, and Accord Healthcare., among others.

• In May 2024, OrganOx Ltd. officially opened a new 18,000 square-foot global research, development, and production headquarters in Oxford, UK. The company developed the world's first normothermic liver perfusion device, the metra, which has gained rapid market adoption and improved patient outcomes. The new facility opening is a major milestone for the company, providing OrganOx stakeholders access to world-class facilities and technologies.
• In October 2021, Paragonix Technologies, the leading provider of donor organ preservation and transport systems, announced the clinical and commercial launch of the LIVERguard Donor Liver Preservation System in both the US and Europe. Additionally, they have launched the GUARDIAN-LIVER (Global Utilization and Registry Database for Improved preservAtion of doNor LIVERs) global registry.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com